Loading…

4CPS-045 Value of the clinical pharmacist in the pharmacokinetic monitoring of antimicrobials: health outcomes

BackgroundThere has been a marked rise in the prescription of vancomycin and aminoglycosides over recent years due to the increase in infections caused by multi-resistant microorganisms. The measurement of their plasma concentrations (Pcs) is necessary to correctly adjust the dosage and minimise the...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2019-03, Vol.26 (Suppl 1), p.A88-A89
Main Authors: Alañon Pardo, MM, Conde García, MC, Notario Dongil, C, Marcos de la Torre, A, Fraga Fuentes, D, Andrés Navarro, N
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundThere has been a marked rise in the prescription of vancomycin and aminoglycosides over recent years due to the increase in infections caused by multi-resistant microorganisms. The measurement of their plasma concentrations (Pcs) is necessary to correctly adjust the dosage and minimise the risk of nephrotoxicity.PurposeTo investigate pharmaceutical interventions (PIs) during the pharmacokinetic monitoring of hospitalised patients receiving vancomycin or gentamicin, and to analyse the health outcomes of monitored patients.Material and methodsWe conducted a prospective observational study (May–September 2018) of PIs by the Clinical Pharmacokinetics Unit of the Pharmacy Department in a 350-bed general hospital. Inclusion criteria were age ≥18 years and treatment with vancomycin or gentamicin. Exclusion criteria were hospitalisation in the ICU and pre-surgical antibiotic prophylaxis. We gathered data on: sex, age and clinical (serum creatinine (Cr), diagnosis), pharmacological (drug, dosage, suspension motive) and pharmacokinetic variables and on PIs (Bayesian estimation of individual pharmacokinetic parameters: PI-1, maintain schedule; PI-2, modify dose and/or interval; and PI-3, temporary suspension to favour renal drug elimination). Treatment effectiveness was defined by the disappearance of initial symptoms/signs (‘clinical recovery’) or of the initial microorganism in control culture (‘microbiological recovery’). ‘Nephrotoxicity’ was defined by Cr ≥1.4 mg/mL or ≥50% above baseline value.ResultsThe study included 61 patients (55.7% female) receiving vancomycin (n=39) or gentamicin (n=22) with mean age of 65.9±19.5 years and mean Cr of 0.7±0.5 mg/mL. The main diagnosis was urinary tract (18.0%) or osteoarticular (14.8%) infection; 104 analytical determinations were conducted (69.2% vancomycin, 30.8% gentamicin); and 57.6% of Pcs were outside the therapeutic range. PIs were: PI-1 (42.3%), PI-2 (53.8%) and PI-3 (3.8%). The reasons for vancomycin versus gentamicin suspension were: ‘clinical/microbiological recovery’ (66.6 vs. 31.8%); ‘therapeutic failure’ (2.6 vs. 0.0%); ‘de-escalation’ (7.7 vs. 22.7%); ‘sequential therapy’ (17.9 vs. 40.9%); ‘severe toxicity’ (0.0 vs. 4.5%); or death (5.2 vs. 0.0%). We observed nephrotoxicity in 2.6% of vancomycin-treated patients and 9.0% of gentamicin-treated patients.ConclusionThe pharmacist adds value to antimicrobial optimisation. Dose or interval modification (PI-2) was the most frequent intervention, increasin
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2019-eahpconf.194